Stock ATXI AVENUE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Analyst Reco. Avenue Therapeutics, Inc.

Equities

ATXI

US05360L4032

Delayed Nasdaq
Other stock markets
 11:22:43 2024-06-07 am EDT 		5-day change 1st Jan Change
3.52 USD -2.22% Intraday chart for Avenue Therapeutics, Inc. +2.33% -70.85%
May. 16 Avenue Therapeutics, Inc Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease) CI
May. 15 Avenue Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Analyst Reco.

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Maxim Starts Coverage on Avenue Therapeutics with Buy Rating, $0.75 Price Target
MT
North American Morning Briefing : Stock Futures Dip as Higher Rate Fears Persist
DJ
Wall Street Set to Open Lower as Mortgage Rates Climb to 16-Year High
MT
US Futures Lower as Mortgage Rates Climb to 16-Year High
MT
Avenue Therapeutics : Biotech incubator taps investors through in-house brokerage
RE
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ATXI Stock
  4. News Avenue Therapeutics, Inc.
  5. Analyst Reco.